GRS is under clinical development by Innovative Pharmacology Research and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect GRS’s likelihood of approval (LoA) and phase transition for Stable Angina took place on 19 May 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their GRS Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

GRS overview

Small molecule is under development for the treatment of stable angina, hypertension and parenchymal hemorrhage. It is an indolinone-3 derivative. The drug candidate is an anti platelet agent which is administered through oral route in the form of capsule. It acts by targeting soluble guanylate cyclase.

Innovative Pharmacology Research overview

Innovative Pharmacology Research (IPHAR) is a drug development company offering services in the fields of synthesis, analytical chemistry, pharmaceutical development, preclinical and clinical trials, document development, drug registration, IP protection, commercialization and investment attraction, and others. IPHAR is headquartered in Tomsk, Russia.

Quick View GRS LOA Data

Report Segments
  • Innovator
Drug Name
  • GRS
Administration Pathway
  • Oral
Therapeutic Areas
  • Cardiovascular
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.